Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Veillonella montpellierensis endocarditis.
Rovery C, Etienne A, Foucault C, Berger P, Brouqui P. Rovery C, et al. Among authors: etienne a. Emerg Infect Dis. 2005 Jul;11(7):1112-4. doi: 10.3201/eid1107.041361. Emerg Infect Dis. 2005. PMID: 16022792 Free PMC article. Review.
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, Terré C, Rigaudeau S, Bordessoule D, Vey N, Gardin C, Dombret H; Acute Leukemia French Association (ALFA). Malfuson JV, et al. Among authors: etienne a. Haematologica. 2008 Dec;93(12):1806-13. doi: 10.3324/haematol.13309. Epub 2008 Oct 6. Haematologica. 2008. PMID: 18838471 Free article.
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Harbi S, Granata A, D'Incan E, Coso D, Chabannon C, Picard C, Etienne A, Calmels B, Schiano JM, Lemarie C, Stoppa AM, Bouabdallah R, Vey N, Blaise D. Devillier R, et al. Among authors: etienne a. Am J Hematol. 2014 Jan;89(1):83-7. doi: 10.1002/ajh.23592. Am J Hematol. 2014. PMID: 24108528 Free article.
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
Devillier R, Bertoli S, Prébet T, Huguet F, Etienne A, Charbonnier A, Rey J, Delabesse E, D'Incan E, Huynh A, Blaise D, Récher C, Vey N. Devillier R, et al. Among authors: etienne a. Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25363834 Free article. No abstract available.
Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D'Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N. Devillier R, et al. Among authors: etienne a. Am J Hematol. 2015 Jan;90(1):E22-4. doi: 10.1002/ajh.23850. Epub 2014 Oct 18. Am J Hematol. 2015. PMID: 25219760 Free article. No abstract available.
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N. Prebet T, et al. Among authors: etienne a. Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721 Free article.
292 results